Business Description
Adicet Bio Inc
NAICS : 541714
SIC : 2834
ISIN : US0070021086
Share Class Description:
LTS:0HX7: Ordinary SharesTotal Employee Number:
102Description
Adicet Bio Inc is a clinical-stage biotechnology company based in the United States that develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its approach uses off-the-shelf donor-derived gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable activity without the need for patient-specific manufacturing. The company's lead candidate, prulacabtagene leucel (prula-cel), is a CD20-targeting CAR gamma delta T cell therapy in development for autoimmune indications. Adicet is also advancing earlier-stage programs, including ADI-212, a gene-edited, armored candidate targeting prostate-specific membrane antigen (PSMA) for oncology. The company's pipeline spans both autoimmune and solid tumor applications. As a clinical-stage business, Adicet does not yet generate product revenue and funds its research and development through equity financings, partnerships, and other capital sources. Its activities are centered on preclinical and clinical development, regulatory interactions, and manufacturing scale-up.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.2 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.1 | |||||
3-Year EPS without NRI Growth Rate | 14.6 | |||||
3-Year FCF Growth Rate | 16.3 | |||||
3-Year Book Growth Rate | -46.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.73 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.86 | |||||
9-Day RSI | 43.46 | |||||
14-Day RSI | 46.53 | |||||
3-1 Month Momentum % | 11.1 | |||||
6-1 Month Momentum % | 30.58 | |||||
12-1 Month Momentum % | 1017.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.71 | |||||
Quick Ratio | 6.71 | |||||
Cash Ratio | 6.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.8 | |||||
Shareholder Yield % | 2.81 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -74.76 | |||||
ROA % | -60.84 | |||||
ROIC % | -262.82 | |||||
3-Year ROIIC % | 131.82 | |||||
ROC (Joel Greenblatt) % | -346.8 | |||||
ROCE % | -68.62 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.68 | |||||
Price-to-Tangible-Book | 0.68 | |||||
EV-to-EBIT | 0.18 | |||||
EV-to-EBITDA | 0.2 | |||||
EV-to-Forward-Revenue | 50.41 | |||||
EV-to-FCF | 0.19 | |||||
Price-to-GF-Value | 19.6 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
| Price-to-Net-Cash | 0.9 | |||||
Earnings Yield (Greenblatt) % | 522.44 | |||||
FCF Yield % | -98.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adicet Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -11.533 | ||
| Beta | 0.908 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 8.71 | ||
| Volatility % | 40.7 | ||
| 14-Day RSI | 46.53 | ||
| 14-Day ATR ($) | 0.473113 | ||
| 20-Day SMA ($) | 9.19252 | ||
| 12-1 Month Momentum % | 1017.73 | ||
| 52-Week Range ($) | 0.4696 - 9.85 | ||
| Shares Outstanding (Mil) | 9.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adicet Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adicet Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-12 | In 171 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-12 | In 171 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 44 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 15:00 | -- | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 10:30 | -- | ||
| Second quarter earnings results for 2026 | 2026-08-05 | -- | ||
| General meeting for 2026 | 2026-06-17 17:00 | -- | ||
| Jefferies Global Healthcare Conference | 2026-06-04 07:35 | -- | ||
| First quarter earnings results for 2026 | 2026-05-13 | -- | ||
| Annual report for 2025 | 2026-03-12 | -- |
Show
Entries
Adicet Bio Inc Frequently Asked Questions
What is Adicet Bio Inc(LTS:0HX7)'s stock price today?
The current price of LTS:0HX7 is $8.82. The 52 week high of LTS:0HX7 is $9.85 and 52 week low is $0.47.
When is next earnings date of Adicet Bio Inc(LTS:0HX7)?
The next earnings date of Adicet Bio Inc(LTS:0HX7) is 2026-11-05 Est..
Does Adicet Bio Inc(LTS:0HX7) pay dividends? If so, how much?
Adicet Bio Inc(LTS:0HX7) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers